OBJECTIVE: To study the expression of Cyclin D1 in nasopharyngeal carcinoma cells processed by epigallocatechin gallate(EGCG) and it's significance, and revealed the anti-tumor mechanism of EGCG against nasopharyngeal carcinoma. METHOD: CNE-2 cells were treated by EGCG at different concentrations, the morphological changes of CNE-2 cells were observed by inverted microscope; the inhibition ratio of cell proliferation was detected by MTT colorimetric method, flow cytometry was used to analyze the changes of cell cycle. The expression of Cyclin D1 mRNA was detected by RT-PCR. RESULT: After treated by EGCG, the CNE2 cells decreased in amount and density, some of which became roll and small; Floating and dead cells can be seen in the inverted microscopy; cell proliferation was significantly inhibited in a time and dose dependent (P < 0.05). CNE-2 cells were arrested at G1/G0 phase. The expression of Cyclin D1 mRNA was down-regulated by EGCG with concentration and action time dependent (P < 0.05). CONCLUSION EGCG resisted nasopharyngeal carcinoma by inhibiting the cell proliferation, The down regulation of Cyclin D1 mRNA expression in a time and dose dependent may be the possible mechanisms.
Carcinoma ; Catechin ; analogs & derivatives ; pharmacology ; Cell Cycle ; drug effects ; Cell Line, Tumor ; Cell Proliferation ; drug effects ; Cyclin D1 ; metabolism ; Humans ; Nasopharyngeal Carcinoma ; Nasopharyngeal Neoplasms ; metabolism ; pathology

Objective:To observe the effect of Risedronate on fracture healing in elderly patients with osteoporotic femoral intertrochanteric fracture.Methods:A retrospective case-control study was conducted on elderly patients with osteoporotic femoral intertrochanteric fractures in our hospital from June 2019 to June 2020.They were followed up regularly for 1 year after proximal femoral nail anti-rotation(PFNA)internal fixation.According to whether the patients took Risedronate during hospitalization, the patients were divided into two groups(PFNA internal fixation combined with Risedronate, 39 cases)and control group(PFNA internal fixation alone, 44 cases). The BMD values before and 1 year after operation were compared between the two groups.Harris score was used to evaluate hip function, Rush score was used to evaluate fracture healing, and the operation-related complications, adverse drug reactions and fractures in other parts were recorded.Results:The fractures of all patients healed 12 months after operation.There were no recurrent fractures in both groups during follow-up.The mean bone mineral density(BMD)T value in healthy side hip was(-2.83±0.46)in Risedronate group and(-3.16±0.42)in control group( t=-3.397, P=0.001). Among the total 83 patients, 39 patients in the Risedronate group had no obvious adverse reactions; 1 patient of 44 patients in the control group had obvious upper abdominal pain and discomfort, accompanied by nausea and lack of appetite.These symptoms improved after stopping the drug. Conclusions:Risedronate taken early after surgery does not affect fracture healing and can improve bone mineral density of healthy side hip.